Level Bio AB (publ) (NGM:LEVBIO)

Market Cap	20.52M
Revenue (ttm)	27.40M
Net Income (ttm)	-6.25M
Shares Out	68.40M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Average Volume	35,341
Open	n/a
Previous Close	0.2800
Day's Range	n/a
52-Week Range	0.2000 - 0.4500
Beta	0.52
RSI	49.87
Earnings Date	Aug 15, 2025

About Level Bio AB

Level Bio AB (publ) manufactures and distributes cutting-edge solutions in the Nordic region and internationally. It also develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to Level Bio AB (publ) in May 2024. Level Bio AB (publ) was incorporated in 1998 and is headquartered in Stockholm, Sweden.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1998
• Employees: 11
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: LEVBIO

Financial Performance

In 2024, Level Bio AB's revenue was 25.10 million, a decrease of -3.83% compared to the previous year's 26.10 million. Losses were -7.87 million, -16.92% less than in 2023.